Nuvectis Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Nuvectis Pharma
NVCT Stock  USD 6.74  0.37  5.81%   
Nuvectis Pharma financial statements provide useful quarterly and yearly information to potential Nuvectis Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nuvectis Pharma financial statements helps investors assess Nuvectis Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nuvectis Pharma's valuation are summarized below:
Market Capitalization
123.1 M
Earnings Share
(1.16)
There are currently ninety-seven fundamental ratios for Nuvectis Pharma that can be evaluated and compared over time across peers in the industry. All traders should check Nuvectis Pharma's last-minute fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 61.5 M in 2025. Enterprise Value is likely to drop to about 52.5 M in 2025
Check Nuvectis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvectis Pharma's main balance sheet or income statement drivers, such as Interest Expense of 179.9 K, Selling General Administrative of 4.6 M or Selling And Marketing Expenses of 13.2 K, as well as many indicators such as Price To Sales Ratio of 510, Dividend Yield of 0.0 or PTB Ratio of 10.05. Nuvectis financial statements analysis is a perfect complement when working with Nuvectis Pharma Valuation or Volatility modules.
  
Check out the analysis of Nuvectis Pharma Correlation against competitors.
For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.

Nuvectis Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.5 M22.1 M9.8 M
Slightly volatile
Total Current Liabilities4.3 M8 M1.8 M
Slightly volatile
Accounts Payable1.9 M3.2 M743.2 K
Slightly volatile
Cash13.9 M22 M9 M
Slightly volatile
Cash And Short Term Investments13.9 M22 M9 M
Slightly volatile
Common Stock Shares Outstanding14.8 M17.9 M13.3 M
Slightly volatile
Liabilities And Stockholders Equity17.6 M22.1 M17.5 M
Very volatile
Other Current Assets64.5 K67.8 K106 K
Pretty Stable
Total Liabilities8.5 M8 M3 M
Slightly volatile
Total Current Assets14.1 M22.1 M9.1 M
Slightly volatile
Non Currrent Assets Other659.2 K741.6 K808.5 K
Slightly volatile
Other Assets659.2 K741.6 K808.5 K
Slightly volatile
Other Stockholder Equity42 M76.4 M15.9 M
Slightly volatile
Deferred Long Term Liabilities659.2 K741.6 K808.5 K
Slightly volatile
Capital Surpluse37 M41.6 M45.3 M
Slightly volatile
Common Stock17.9 B20.4 B15.5 B
Slightly volatile

Nuvectis Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.6 M8.6 M1.9 M
Slightly volatile
Selling And Marketing Expenses13.2 K16.1 K11.3 K
Slightly volatile
Other Operating Expenses15.1 M26.3 M6 M
Slightly volatile
Total Operating Expenses15.1 M26.3 M6 M
Slightly volatile
Total Other Income Expense Net769.2 K732.5 K152.9 K
Slightly volatile
Net Interest Income573.6 K546.2 K112 K
Slightly volatile
Interest Income573.6 K546.2 K112 K
Slightly volatile
Research Development14 M17.7 M10.9 M
Slightly volatile
Cost Of Revenue20.2 M26.3 M15.2 M
Slightly volatile

Nuvectis Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Change In Working Capital1.9 M2 M694.1 K
Slightly volatile
Total Cash From Financing Activities20.2 M17.4 M16.5 M
Slightly volatile
End Period Cash Flow12.3 M22 M5 M
Slightly volatile
Change To Netincome1.5 M1.5 M1.8 M
Slightly volatile
Change To Liabilities5 M4.8 M1.2 M
Slightly volatile
Stock Based Compensation3 M5.4 M2.3 M
Slightly volatile
Begin Period Cash Flow12.1 M23 M9.2 M
Slightly volatile
Issuance Of Capital Stock3.8 M3.9 M14.2 M
Slightly volatile
Sale Purchase Of Stock22.2 M25 M27.3 M
Slightly volatile
Cash And Cash Equivalents Changes11.4 M12.8 M14 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio510573625
Slightly volatile
Stock Based Compensation To Revenue9.1710.3111.2418
Slightly volatile
EV To Sales402453494
Slightly volatile
Payables Turnover9.929.511.2837
Slightly volatile
Sales General And Administrative To Revenue32.2636.2839.5598
Slightly volatile
Research And Ddevelopement To Revenue71.0279.8987.1072
Slightly volatile
Cash Per Share0.871.110.6379
Slightly volatile
Days Payables Outstanding34.4939.7633.315
Slightly volatile
Income Quality0.790.820.7428
Slightly volatile
Net Debt To EBITDA0.620.750.5368
Slightly volatile
Current Ratio2.262.472.482
Slightly volatile
Graham Number3.124.521.4546
Slightly volatile
Revenue Per Share0.00940.01060.0116
Slightly volatile
Interest Debt Per Share0.00940.01060.0116
Slightly volatile
Days Of Payables Outstanding34.4939.7633.315
Slightly volatile
Ebt Per Ebit1.091.121.0107
Slightly volatile
Effective Tax Rate0.01480.01410.0054
Slightly volatile
Quick Ratio2.262.472.482
Slightly volatile
Net Income Per E B T1.091.131.0116
Slightly volatile
Cash Ratio2.222.462.4459
Slightly volatile
Price Sales Ratio510573625
Slightly volatile
Asset Turnover0.00580.00660.0072
Slightly volatile

Nuvectis Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap61.5 M116.8 M56.2 M
Slightly volatile
Enterprise Value52.5 M99.6 M51.7 M
Slightly volatile

Nuvectis Fundamental Market Drivers

Cash And Short Term Investments19.1 M

Nuvectis Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Nuvectis Pharma Financial Statements

Nuvectis Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Nuvectis Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Nuvectis Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nuvectis Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue26.3 M20.2 M
Stock Based Compensation To Revenue 10.31  9.17 
Sales General And Administrative To Revenue 36.28  32.26 
Research And Ddevelopement To Revenue 79.89  71.02 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(116.18)(121.99)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Nuvectis Stock Analysis

When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY